Markushovd (Talk | contribs) |
Markushovd (Talk | contribs) |
||
Line 14: | Line 14: | ||
.goldborder { | .goldborder { | ||
border-top: 4px dotted gold; | border-top: 4px dotted gold; | ||
− | border-bottom: | + | border-bottom: 4px dotted gold; |
− | + | ||
} | } | ||
Revision as of 12:52, 7 November 2018
Fast detection of vulvovaginal Candida albicans infections using CRISPR/dCas9
UiOslo_Norway
Awarded Best Diagnostic ProjectNominated Best Presentation
During their lifetime 75% of women will experience a Candida albicans infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by C. albicans. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult.
Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for C. albicans infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on C. albicans specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of C. albicans DNA.
Contact information: uioslonorway (at) gmail dot com